報價延遲最少15分鐘:2024/12/24 13:50 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
36.53 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.44/-3.73
|
|
企業價值
7.10B
|
| 資產負債 |
|
每股賬面淨值
4.20
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
787.65M
|
|
每股收益
3.90
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/24 13:50 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. |